• Home
  •  / Cytokinetics

Cytokinetics

OverviewSuggest Edit

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics holds the exclusive right to develop and commercialize tirasemtiv throughout the world. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights.
TypePublic
Founded1997
HQSouth San Francisco, USMap
Websitecytokinetics.com
Employee Ratings3.6More
Culture scoreCMore
View Jobs (8)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)130(-5%)
Job Openings8
Revenue (FY, 2019)$26.9 M(-14%)
Share Price (Mar 2020)$11.8 (+3%)

Key People/Management at Cytokinetics

Durga Bobba

Durga Bobba

VP, Global Franchise General Manager, Cardiovascular
Robert I. Blum

Robert I. Blum

President, Chief Executive Officer & Director
Daniel R. Casper

Daniel R. Casper

VP, Information Technology
Bonnie A. Charpentier

Bonnie A. Charpentier

SVP, Regulatory Affairs and Compliance
Erin Donnelly

Erin Donnelly

VP, Portfolio & Project Management
David W. Cragg

David W. Cragg

Chief Human Resources and Administration Officer
Show more

Cytokinetics Office Locations

Cytokinetics has an office in South San Francisco
South San Francisco, US (HQ)
280 E Grand Ave
Show all (1)

Cytokinetics Financials and Metrics

Cytokinetics Revenue

Cytokinetics's revenue was reported to be $26.87 m in FY, 2019
USD

Revenue (FY, 2019)

26.9m

Net income (FY, 2019)

(121.7m)

EBIT (FY, 2019)

(98.9m)

Market capitalization (27-Mar-2020)

698.5m

Closing stock price (27-Mar-2020)

11.8

Cash (31-Dec-2019)

36.4m

EV

714.0m
Cytokinetics's current market capitalization is $698.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

4.0m7.6m30.6m46.9m28.7m106.4m13.4m31.5m26.9m

Revenue growth, %

53%(39%)271%

General and administrative expense

13.6m12.4m15.1m17.3m19.7m27.8m36.5m31.3m39.6m

R&D expense

37.2m35.6m49.5m44.4m46.4m59.9m90.3m89.1m86.1m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

1.1m1.4m1.8m1.8m1.7m821.0k1.0m4.5m8.0m7.8m9.4m4.4m6.5m7.9m8.4m5.8m59.0m4.2m3.1m6.2m5.3m6.2m10.6m8.5m7.1m6.1m

General and administrative expense

4.2m3.2m3.1m2.6m3.0m3.6m3.7m3.6m4.3m4.5m4.0m4.4m4.5m5.3m6.8m7.1m7.2m8.1m8.4m9.7m9.3m8.0m7.2m9.4m9.8m9.8m

R&D expense

10.5m8.9m8.7m8.2m8.8m9.8m12.3m13.4m12.5m11.7m11.4m9.0m12.6m11.6m13.5m9.7m19.3m19.3m19.8m24.9m22.1m21.6m21.4m23.5m24.0m20.2m

Operating expense total

14.7m12.1m11.8m10.8m11.8m13.5m16.1m17.1m16.7m16.2m15.4m13.3m17.1m16.8m20.4m16.8m26.6m27.4m28.2m34.6m31.4m29.6m28.6m33.0m33.9m30.0m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

18.8m14.9m20.2m20.2m65.1m66.9m125.2m42.3m36.4m

Accounts Receivable

1.1m2.2m5.2m

Prepaid Expenses

2.1m2.4m1.6m1.3m1.7m4.3m2.2m3.5m

Inventories

Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

23.8m18.6m17.8m63.7m15.4m13.2m17.1m19.3m13.3m12.4m12.9m22.5m24.8m26.0m42.3m27.7m30.3m49.4m100.7m116.3m115.0m47.0m27.6m39.4m34.4m39.6m

Accounts Receivable

10.0m37.0k236.0k9.2m4.2m9.0m6.6m

Prepaid Expenses

2.9m2.2m2.1m2.5m3.2m1.7m2.0m1.7m1.6m2.0m1.8m2.0m2.7m2.7m6.3m2.6m3.6m4.9m4.4m2.3m1.7m1.9m3.1m2.5m3.9m

Current Assets

69.8m59.9m45.2m93.0m78.8m63.7m93.6m83.3m86.1m80.1m81.5m110.8m107.9m100.5m106.1m96.6m148.2m211.0m317.0m322.0m272.3m244.2m227.3m186.4m185.0m176.5m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(47.9m)(40.4m)(33.7m)(14.6m)(37.5m)16.5m(127.8m)(106.3m)(121.7m)

Depreciation and Amortization

1.3m591.0k433.0k490.0k589.0k741.0k1.9m1.2m1.3m

Accounts Payable

162.0k690.0k1.7m(2.2m)755.0k1.7m1.5m(1.5m)4.4m

Cash From Operating Activities

(45.6m)(33.4m)(7.7m)(44.8m)4.9m37.0m(101.8m)(101.2m)(90.9m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(25.3m)(36.0m)(9.9m)(18.9m)(28.9m)(12.6m)(27.7m)(40.2m)(8.7m)(17.1m)(23.1m)(8.9m)(19.4m)(8.8m)(12.5m)(24.1m)7.8m(25.9m)(54.9m)(87.3m)(30.3m)(57.8m)(79.8m)(29.4m)(61.5m)(91.1m)

Depreciation and Amortization

813.0k1.1m178.0k322.0k462.0k124.0k244.0k345.0k105.0k227.0k353.0k145.0k292.0k170.0k340.0k517.0k421.0k860.0k1.3m673.0k1.3m1.6m286.0k566.0k902.0k

Accounts Payable

(41.0k)422.0k(257.0k)(137.0k)334.0k(800.0k)(72.0k)(103.0k)(2.1m)(2.5m)(1.9m)95.0k311.0k1.9m(1.5m)841.0k(1.3m)(726.0k)(1.9m)1.5m(2.8m)(3.9m)(3.2m)(1.2m)1.4m(352.0k)

Cash From Operating Activities

(25.4m)(34.6m)(8.7m)(17.4m)(26.3m)(12.2m)(5.6m)4.7m(17.8m)(27.2m)(36.7m)34.4m25.2m(17.5m)(28.7m)(40.8m)(20.9m)(52.2m)(77.7m)(29.8m)(56.7m)(88.9m)(26.9m)(51.6m)(71.9m)
show all
USDY, 2019

EV/EBIT

-7.2 x

EV/CFO

-7.9 x

Financial Leverage

-26.5 x
Show all financial metrics

Cytokinetics Online and Social Media Presence

Cytokinetics's Trends

Embed Graph

Cytokinetics Company Culture

  • Overall Culture

    C

    69/100

  • CEO Rating

    A-

    80/100

  • Compensation

    A+

    97/100

Learn more on Comparably

Cytokinetics News and Updates

March 04, 2020

Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis

SOUTH SAN FRANCISCO, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the treatment of amyotrophic lateral sclerosis (ALS). Previously re…
March 03, 2020

Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure

In Vitro Studies Demonstrate Cardiac Troponin Activator Selectively Activates Cardiac Muscle Fibers with Little Effect on Slow Skeletal Muscle or Fast Skeletal Muscle
February 20, 2020

Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting

Preclinical Studies Demonstrate Distinct Binding Site for Next-Generation Cardiac Myosin Inhibitor Preclinical Studies Demonstrate Distinct Binding Site for Next-Generation Cardiac Myosin Inhibitor
February 06, 2020

Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

Second Interim Analysis in GALACTIC-HF Expected to Occur in Q1 2020
January 22, 2020

Cytokinetics Announces Recipients of Second Annual Communications Fellowship Grants

Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach
January 13, 2020

Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones

Top-line Results from GALACTIC-HF Now Expected in Q4 2020; Commercial Readiness Underway
Show more

Cytokinetics Blogs

March 20, 2020

CYTOKINETICS TO ANNOUNCE BASELINE CHARACTERISTICS FROM GALACTIC-HF DURING ACC.20/WCC

CYTOKINETICS TO ANNOUNCE BASELINE CHARACTERISTICS FROM GALACTIC-HF DURING ACC.20/WCC Content Import Fri, 03/20/2020 - 16:00 CYTOKINETICS TO ANNOUNCE BASELINE CHARACTERISTICS FROM GALACTIC-HF DURING ACC.20/WCC 03/20/20 This release is a backfill from a News Wir…
March 03, 2020

Cytokinetics Reports Fourth Quarter 2019 Financial Results

GALACTIC-HF Continuing Following Second Planned Interim Analysis;  Top-line Results for GALACTIC-HF Expected in Q4 2020 Company Provides 2020 Financial Guidance; More Than Two Years of Cash Runway Based on 2020 Guidance SOUTH SAN FRANCISCO, Calif. , March 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics,
February 28, 2020

Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day

SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq: CYTK) today announced that on February 29 it is joining the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day®,
February 18, 2020

Cytokinetics to Announce Fourth Quarter Results on March 3, 2020

SOUTH SAN FRANCISCO, Calif. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on March 3, 2020 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
January 28, 2020

Q4 2019 Cytokinetics, Inc. Earnings Conference Call

Q4 2019 Cytokinetics, Inc. Earnings Conference Call marco.guevara@… Tue, 01/28/2020 - 11:58 Q4 2019 Cytokinetics, Inc. Earnings Conference Call Display "add to calendar" true Event Type Earnings Conference Call Click here for …
January 06, 2020

Cytokinetics Announces Start of REDWOOD-HCM, a Phase 2 Clinical Trial of CK-3773274

Next-Generation Cardiac Myosin Inhibitor Advances In Clinical Trial Designed to Assess Effects Using Two-Week Dose Titration Schedule SOUTH SAN FRANCISCO, Calif. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that REDWOOD-HCM ( R andomized E valuation
Show more

 Cytokinetics Frequently Asked Questions

  • When was Cytokinetics founded?

    Cytokinetics was founded in 1997.

  • Who are Cytokinetics key executives?

    Cytokinetics's key executives are Durga Bobba, Robert I. Blum and Daniel R. Casper.

  • How many employees does Cytokinetics have?

    Cytokinetics has 130 employees.

  • What is Cytokinetics revenue?

    Latest Cytokinetics annual revenue is $26.9 m.

  • What is Cytokinetics revenue per employee?

    Latest Cytokinetics revenue per employee is $206.7 k.

  • Who are Cytokinetics competitors?

    Competitors of Cytokinetics include Jazz Pharmaceuticals, Bausch Health Companies and STERIS.

  • Where is Cytokinetics headquarters?

    Cytokinetics headquarters is located at 280 E Grand Ave, South San Francisco.

  • Where are Cytokinetics offices?

    Cytokinetics has an office in South San Francisco.

  • How many offices does Cytokinetics have?

    Cytokinetics has 1 office.